FABP1 and metabolic dysfunction-associated steatotic liver disease: However, due to its small molecular weight (15 kDa) and its intracellular location, FABP1 is released in the serum in increased quantities in several pathological conditions involving hepatocyte injury and was reported to have a pathogenic role in NAFLD in diabetic patients [40].